Patents by Inventor Charles Willis Lugar
Charles Willis Lugar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220073526Abstract: The invention provides certain difluorocyclohexyl-imidazopyridazinyl-imidazolidinone compounds of formula II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula II to treat certain symptoms of psoriasis, rheumatoid arthritis or multiple sclerosis.Type: ApplicationFiled: January 3, 2020Publication date: March 10, 2022Inventors: David Andrew Coates, Kwame Frimpong, William Glen Holloway, Brian Spencer Jones, Adam Marc Levinson, Charles Willis Lugar, III, Michael Enrico Richett, Brian Morgan Watson, Michael Edward Woodman
-
Patent number: 11008336Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof, formula (A).Type: GrantFiled: February 27, 2018Date of Patent: May 18, 2021Assignee: Eli Lilly and CompanyInventors: Christian Alexander Clarke, Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Rudyk, Selma Sapmaz, Ryan Edward Stites, Grant Mathews Vaught
-
Patent number: 10603320Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof. Formula (I).Type: GrantFiled: February 27, 2018Date of Patent: March 31, 2020Assignee: Eli Lilly and CompanyInventors: Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Catherine Eugenie Rudyk, Selma Sapmaz, Ryan Edward Stites
-
Publication number: 20200048279Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof, formula (A).Type: ApplicationFiled: February 27, 2018Publication date: February 13, 2020Inventors: Christian Alexander Clarke, Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Rudyk, Selma Sapmaz, Ryan Edward Stites, Grant Mathews Vaught
-
Publication number: 20200009139Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof. Formula (I).Type: ApplicationFiled: February 27, 2018Publication date: January 9, 2020Inventors: Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Catherine Eugenie Rudyk, Selma Sapmaz, Ryan Edward Stites
-
Publication number: 20090069400Abstract: Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.Type: ApplicationFiled: January 17, 2007Publication date: March 12, 2009Inventors: Thomas John Bleisch, Christian Alexander Clarke, Jeffrey Alan Dodge, Scott Alan Jones, Jose Eduardo Lopez, Charles Willis Lugar, III, Brian Stephen Muehl, Timothy Ivo Richardson, Ying Kwong Yee, Kuo-Long Yu
-
Patent number: 7217734Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate cancer.Type: GrantFiled: November 7, 2002Date of Patent: May 15, 2007Assignee: Eli Lilly and CompanyInventors: Jeffrey Alan Dodge, Venkatesh Krishnan, Charles Willis Lugar, III, Blake Lee Neubauer, Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
-
Patent number: 6992097Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.Type: GrantFiled: June 3, 2003Date of Patent: January 31, 2006Assignee: Eli Lilly and CompanyInventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
-
Publication number: 20040249167Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor &bgr; agonists. Such agonists are useful for the treating Estrogen Receptor &bgr; mediated diseases such as prostate cancer.Type: ApplicationFiled: April 20, 2004Publication date: December 9, 2004Inventors: Jeffrey Alan Dodge, Venkatesh Krishnan, Charles Willis Lugar, Blake Lee Neubauer, Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
-
Patent number: 6828331Abstract: What is disclosed are growth hormone secretagogues, and their uses, of the formula wherein R1 is C6H5CH2OCH2—, C6H5 (CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6 alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1 to C6 alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6 alkoxy or phenyl; and R4 is H or CH3, or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: July 25, 2001Date of Patent: December 7, 2004Assignee: Eli Lilly and CompanyInventors: Jeffrey Alan Dodge, Charles Willis Lugar, III
-
Publication number: 20040122234Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.Type: ApplicationFiled: June 3, 2003Publication date: June 24, 2004Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
-
Patent number: 6639076Abstract: This invention relates to novel compounds of formula I wherein A, B, D, E, G, J, L, X, V are as defined in the specification, and the compounds are useful in the modulation of endogenous growth hormone levels in a mammal.Type: GrantFiled: April 17, 2001Date of Patent: October 28, 2003Assignee: Eli Lilly and CompanyInventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, James Densmore Copp, William Harlan Gritton, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
-
Patent number: 6630508Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor &bgr; agonists. Such agonists are useful for treating Estrogen Receptor &bgr; mediated diseases such as prostate cancer.Type: GrantFiled: January 22, 2003Date of Patent: October 7, 2003Assignee: Eli Lilly and CompanyInventors: Jeffrey Alan Dodge, Venkatesh Krishnan, Charles Willis Lugar, III, Blake Lee Neubauer
-
Patent number: 6509356Abstract: A class of substituted benzylnaphthylene compounds of the structure where R1 and R2 are independently hydrogen, alkyl of one to six carbon atoms, acyl of two to six carbon atoms, or phenacyl; X is —(CH2)1-6; Y is absent or is selected from 1,4-piperazinylene; ureido; N-(lower alkyl)ureido; N′-(lower alkyl)ureido; or N, N′-(di-lower alkyl ureido; and Z is 1-, 2- or 3-pyrrolidinyl; 1-, 2-, or 3-[1-(lower alkyl) pyrrolidinyl]; 1- 2-, 3- or 4-piperidinyl; 1-, 2-, 3- or 4-[1-lower alkyl)piperidinyl]; N,N-dialkyl; 1-azepinyl; 1- or 2-naphthylamino, 4-morpholinyl, dimethyl-4-morpholinyl, 3-azaspiro[5.Type: GrantFiled: August 4, 1998Date of Patent: January 21, 2003Assignee: Eli Lilly and CompanyInventors: Jeffrey Alan Dodge, Andrew Lawrence Glasebrook, Charles Willis Lugar, III
-
Patent number: 6218425Abstract: Certain B-nor-6-thiaequilenin compounds substituted at the 3-position with hydroxy and at the 8-position with hydroxy or alkoxy of from one to four carbon atoms are selective estrogen receptor modulators and are useful in the treatment of estrogen-related disorders including such conditions as osteoporosis, hyperlipidemia, estrogen-dependent breast cancer, uterine fibrosis, endometriosis, and restenosis.Type: GrantFiled: July 29, 1997Date of Patent: April 17, 2001Assignee: Eli Lilly and CompanyInventors: Jeffrey Alan Dodge, Charles Willis Lugar, III
-
Patent number: 5959103Abstract: The invention provides naphthofluorene compounds, intermediates, formulations, processes, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions, including hyperlipidemia, and estrogen-dependent cancer.Type: GrantFiled: September 30, 1998Date of Patent: September 28, 1999Assignee: Eli Lilly and CompanyInventors: Henry Uhlman Bryant, Jeffrey Alan Dodge, Charles Willis Lugar, III
-
Patent number: 5889000Abstract: The invention provides naphthofluorene compounds, intermediates, formulations, processes, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions, including hyperlipidemia, and estrogen-dependent cancer.Type: GrantFiled: September 22, 1997Date of Patent: March 30, 1999Assignee: Eli Lilly and CompanyInventors: Henry Uhlman Bryant, Jeffrey Alan Dodge, Charles Willis Lugar, III
-
Patent number: 5811421Abstract: The present invention provides compounds of formula ##STR1## wherein R.sup.1 is --H, --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCOC.sub.6 H.sub.5, --OCO(C.sub.1 -C.sub.6 alkyl), or --OSO.sub.2 (C.sub.4 -C.sub.6 alkyl);R.sup.2 is C.sub.1 -C.sub.6 alkyl or C.sub.5 -C.sub.7 cycloalkyl which is optionally substituted with 1 to 3 substitutents selected from the group consisting of C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, amino, nitro, and halo;X is --CH(OH)-- or --CH.sub.2 --;M is --CH.sub.2 CH.sub.2 -- or --CH.dbd.CH--;n is 2 or 3; andR.sup.3 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof. Also provided are methods of using the compounds of the present invention for the treatment of various medical indications associated with post-menopausal syndrome, uterine fibroid disease, endometriosis, and aortal smooth muscle cell proliferation.Type: GrantFiled: July 16, 1996Date of Patent: September 22, 1998Assignee: Eli Lilly and CompanyInventors: Jeffrey Alan Dodge, Kennan Joseph Fahey, Charles David Jones, Charles Willis Lugar, III